Last updated on June 2018

A Study of LY3002813 and LY3202626 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)

Brief description of study

The purpose of this study is to evaluate the safety, tolerability and efficacy of LY3002813 alone and in combination with LY3202626 in early symptomatic Alzheimer's disease.

Clinical Study Identifier: NCT03367403

Contact Investigators or Research Sites near you

Start Over

Ramon Gil

Parkinson's Disease Treatment Center of SW Florida
Port Charlotte, FL United States
  Connect »